In addition, the financial report also shows that Danaher currently has a strong balance sheet and more than 8 billion US dollars of acquisition funds, which may promote future performance growth. Industrial technology business revenue was 913 million US dollars, an increase of 5.5% compared with the same period last year, operating profit margin increased by 30 basis points to 23.8%. The dental department’s revenue was US$528 million, an increase of 2.5%year-on-year the operating margin fell by 50 basis points to 14.8%. Environmental protection revenue was 876 million US dollars, an increase of 6% compared with last year’s profit margin, the operating profit of this part of the business decreased by 60 basis points to 21.0%. Test and measurement business revenue was 857 million US dollars, which was the same as last year compared with last year’s figure, the operating profit of this business dropped by 250 basis points to 18.4%. Danaher’s Q2 revenue was slightly lower than Zacks’ consensus estimate of $4.968 billion.Īmong them, the total revenue of life sciences and diagnostics was US$1.79 billion, a year-on-year increase of 7% the operating profit margin for the quarter increased by 140 basis points to 15.8%. The financial report shows that Danaher’s Q2 total sales were 4.964 billion US dollars, a year-on-year increase of 5%, and core revenue increased by 3%. Recently, Danaher announced its Q2 financial report. The company's shares have traded between $43.95 and $78.27 in the last year.Danaher’s Q2 earnings disappointment, split rumors clamoring In December, Beckman Coulter was linked to potential acquirers including Blackstone Group LP and Apollo Global Management LLC. Chairman, CEO and President Scott Garrett resigned unexpectedly in September after five years with the company. It reported a drop in its second-quarter profit and cut its annual guidance because sales from developed markets were down. The Food and Drug Administration said it appeared the company made changes to the test kits without approval July. The company said in March is would have to get new regulatory approval for its AccuTnl test kit, which is used to determine is a patient has suffered a heart attack. It also makes Craftsman tools for the retailer Sears.īeckman Coulter has not reported its full-year results, but it had $2.68 billion in revenue in the first nine months of the year.īeckman Coulter has dealt with several recent setbacks.
Danaher shares rose $1.71, or 3.6 percent, to $49.69.ĭanaher, which is based in Washington, D.C., reported $13.2 billion in revenue in 2010, with $2.3 billion from the life sciences business. Shares of Beckman Coulter surged $7.35, or 9.8 percent, to $82.52 in morning trading. Beckman Coulter said its board unanimously supports the sale. Closing depends on a majority of Beckman Coulter shareholders tendering their shares in favor of the deal. The deal is expected to be completed in the first half of the year. Danaher valued the purchase at $6.8 billion including Beckman Coulter's debt and its cash on hand. 9 - the day before the acquisition rumors first surfaced. That would make the life sciences unit Danaher's largest.īeckman Coulter, which is based in Brea, Calif., had reportedly put itself up for sale in December.ĭanaher has agreed to pay $83.50 per Beckman Coulter share, a 45 percent premium over Beckman's share price on Dec. It will become part of Danaher's life sciences and diagnostics business if the deal goes through. makes products that simplify and automate biomedical testing. said Monday it agreed to buy medical testing instrument maker Beckman Coulter for about $5.87 billion.īeckman Coulter Inc. Medical and industrial instruments maker Danaher Corp.
0 kommentar(er)
